Kringle Pharma, Inc. (4884) Press Release
Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury
Earlier from Kringle Pharma
- Kringle Pharma: Update on the Investigator-initiated Phase 2 Study in Patients with ALS
- Kringle Pharma: Files Patent Application for Treatment of Chronic Spinal Cord Injury
- Kringle Pharma: Appoints Hideyuki Okano, M.D., Ph.D. as Scientific Advisor
- Kringle Pharma: Financial Results for the Three Months Ended December 31, 2021(Non-consolidated)